Meal Replacement: How the GLP-1 Consumer Is Resetting Convenience Nutrition
Updated: 4 days ago
Executive summary. Meal replacement has stopped being a diet product and become the front line of a structural change in how people eat. One in five American households now includes a user of a GLP-1 weight-loss medication, those households are buying less food and more protein, and the largest food companies are reformulating around them. Strategic Revenue Insights estimates the global meal replacement market at USD 17.50 billion in 2025, rising to USD 34.10 billion by 2035 at a 6.9 percent compound annual growth rate. The companies that will capture that growth are the ones that treat meal replacement as clinically credible, protein-dense nutrition for a medicated consumer, not as a shake for dieters. This article sets out five lessons from the brands and retailers moving first, with takeaways for strategy, product, regulation, channels, pricing and revenue.
The structure of that growth matters more than the headline. Strategic Revenue Insights' Meal Replacement Market research finds that ready-to-drink shakes are the largest product segment, that plant-based formulations are the fastest growing by source, that supermarkets and hypermarkets remain the largest channel while online retail gains share, and that North America is the largest regional market while Asia Pacific is the fastest growing. The research identifies lifestyle-related conditions such as obesity and diabetes, demand for convenient nutrition, fitness culture, e-commerce and rising incomes in Asia as the forces behind the forecast, and price competition, labelling and health-claim regulation, supply chain pressure and shifting dietary preferences as the forces working against it.
What the forecast captures only in outline is the speed at which the buyer has changed. Numerator's household tracker reports that 22 percent of United States households now include a current GLP-1 user, double the share in October 2023, and PwC's 2026 survey puts the figure at 21 percent, up from 9 percent in January 2025. A medicated consumer eats less, wants more protein and fibre per calorie, and is prepared to pay for products that fit a medical regimen. That consumer is now a mainstream segment, and the meal replacement category, which was built for weight management long before the drugs arrived, is the product format most directly in their path.
Why the Meal Replacement Market Is Entering a New Phase
Three structural forces are converging.
The medicated consumer has become a mass segment. A Cornell University study published in the Journal of Marketing Research, using Numerator panel data, found that households reduce grocery spending by an average of 5.3 percent within six months of starting a GLP-1 medication, and by more than 8 percent among higher-income households, with the reduction persisting for at least a year among continuing users. Spending on chips and savoury snacks fell 11.5 percent, sweet bakery 8.5 percent and soft drinks 6.8 percent, while spending on yogurt, fresh produce, meat snacks and nutrition bars rose. Boston Consulting Group's survey of more than 1,500 users found that active users expect to raise spending on fruit and vegetables by 15 percent and on high-protein foods by 11 percent. The basket is shrinking and shifting at the same time.
Protein has become the organising principle of the category. Circana's Eating Patterns in America 2026 report finds that 48 percent of adults are seeking more protein in their diets, up seven points in a year, and that 65 percent of GLP-1 users are doing so. In foodservice, 12 percent of commercial meals are now described as high protein, with those occasions up 11 percent year on year. Meal replacement is a protein-delivery format by design, and the demand curve has moved toward it.
Regulation is redefining what counts as healthy. The United States Food and Drug Administration's updated definition of the "healthy" nutrient content claim took effect in April 2025 with a compliance date of February 2028, its proposed front-of-package Nutrition Info box, published in January 2025, is awaiting a final rule, and in August 2026 the FDA and the Department of Agriculture submitted a proposed federal definition of ultra-processed foods for final review. The Department of Agriculture has confirmed that "GLP-1 friendly" has no regulatory standard. A category that sells on nutritional claims is about to be measured against official definitions.
These forces explain SRI's forecast of a market that roughly doubles between 2025 and 2035, with growth concentrated in protein-dense, clinically credible formats sold through the channels where the medicated consumer already shops.
Five Lessons From the Brands and Retailers Moving First
The brands, ingredient suppliers and retailers converting meal replacement from a diet aisle into a nutrition platform share a recognisable pattern. We have distilled it into five lessons, each followed by a takeaway for a specific leadership function.
Lesson 1: The Buyer Has Changed From Dieter to Patient
For three decades the meal replacement consumer was someone trying to lose weight through willpower, and the category was built around calorie control, portion substitution and short bursts of use. The GLP-1 consumer is different in every respect that matters. Their appetite is suppressed pharmacologically, so the product does not need to make them feel full; it needs to make the calories they do eat count. They are under medical supervision, so they read labels for protein, fibre and micronutrients rather than for calories. And they stay: PwC found that 54 percent of users in 2026 had been on the medication for more than a year, up from 38 percent in 2024.
That changes the commercial model. A dieter buys for twelve weeks; a long-term GLP-1 user buys for years, and their needs change as they lose weight, plateau and in many cases taper off. The brands moving first are building for that arc: nutritionally complete products for the active-loss phase, higher-protein maintenance formats for the plateau, and transition products for people coming off the drug who need to manage appetite without it.
SRI's research already lists weight management, sports and fitness, convenience and medical and clinical nutrition as the category's four applications. The GLP-1 consumer collapses the first and the last into one: weight management has become clinical nutrition, and the brands that recognise that are the ones gaining shelf and share.
"The meal replacement customer used to be fighting their appetite. Now their appetite has been switched off by a drug, and the only question is whether what they eat is worth eating."
Takeaway on strategy. Rebuild the category thesis around the medicated consumer, not the dieter. Size the GLP-1 household base in every market, map the three phases of use, and design the portfolio, the messaging and the subscription model for a multi-year relationship. Treat weight management and clinical nutrition as one segment with one evidence standard.
Lesson 2: Protein and Fibre Density Is the New Product Specification
The product brief has been rewritten by the consumer's new physiology. A GLP-1 user eating 20 percent fewer calories cannot afford empty ones, and clinical guidance for users emphasises protein to preserve lean mass, fibre for digestive tolerance and micronutrient completeness. The Cornell data show the market responding before the brands did: households shifted spend toward yogurt, meat snacks and nutrition bars on their own.
The companies moving first have reformulated accordingly. Nestlé launched its Vital Pursuit range in 2024, built around protein, fibre and portion sizes designed for appetite-suppressed consumers, and has said it is using nutritional science and artificial intelligence to identify nutrient combinations for GLP-1 users. Conagra added a GLP-1 friendly designation to its Healthy Choice frozen meals and expanded the line in 2026. Abbott, Glanbia, Herbalife, Huel and BellRing Brands, all named in SRI's competitive landscape, have built their growth on protein-dense formats that fit the brief without having to be reinvented.
SRI's research identifies plant-based formulations as the fastest-growing source segment, and that creates a formulation challenge: delivering high protein quality, fibre and a tolerable texture from plant sources at a price the mass market will pay. The ingredient suppliers that solve that problem will be as important to the category's growth as the brands.
Takeaway on product and R&D. Reformulate the core range to a protein-first, fibre-rich, nutritionally complete specification and publish the numbers on the front of the pack. Build phase-specific formats for active loss, maintenance and transition, invest in plant protein quality and texture, and validate tolerability with real users of the medication. Measure innovation by grams of protein per calorie and by repeat purchase among GLP-1 households, not by flavour launches.
Lesson 3: Clinical Credibility Is the Moat
As the medicated consumer becomes the core buyer, the brands that can speak with medical authority gain an advantage that marketing cannot replicate. Abbott and Nestlé Health Science built their meal replacement businesses in clinical nutrition before the drugs existed, and that heritage now travels into the consumer aisle. Direct-selling incumbents such as Herbalife, Amway, Nu Skin and USANA, all named in SRI's research, have strong distribution but face a credibility test with a consumer who takes advice from a prescriber.
Regulation is reinforcing the moat. The FDA's updated "healthy" definition, the pending front-of-package labelling rule and the forthcoming federal definition of ultra-processed foods will each sort products into categories that a medically supervised consumer will read. "GLP-1 friendly" has no legal meaning, and the brands relying on it as a label rather than as a formulation standard are exposed. SRI's research names labelling and health-claim regulation as a central restraint on the market; for brands with clinical evidence, it is a competitive asset.
"A dieter trusts a label. A patient trusts a study. The meal replacement brands that cannot show the second will lose the customer who now matters most."
Takeaway on regulatory and brand trust. Treat the FDA's "healthy" rule, the front-of-package proposal and the ultra-processed definition as product-design constraints now, not compliance tasks in 2028. Build clinical evidence for the core range, align claims with recognised nutritional guidance for GLP-1 users, and retire marketing language that regulators have said has no standard. Position the brand with prescribers, dietitians and pharmacists, because that is where the consumer's trust now sits.
Lesson 4: The Channel Is Moving Toward the Prescription
SRI's research finds supermarkets and hypermarkets the largest channel, online retail gaining, and pharmacies and drugstores and direct selling as distinct routes to market. The GLP-1 consumer is redrawing that map. Their relationship with the category begins at the point of prescription, whether a physician, a telehealth platform or a pharmacy, and the brands moving first are building presence at that point. Pharmacy adjacency, telehealth bundles, dietitian referral programmes and subscription delivery timed to the medication cycle are becoming the channels that matter.
Retailers are responding too. Trade coverage in 2026 describes supermarkets reorganising assortments and promotions around GLP-1 households, reallocating space from carbohydrate-heavy snacks toward protein, produce and functional nutrition, and building loyalty programmes for the segment. The retailer that becomes the trusted source for the medicated household captures a basket that is smaller but higher value and more loyal.
The direct-selling incumbents have an opportunity as well as a threat: their distributor networks are built for repeat, relationship-based selling, which is what a multi-year medication regimen requires, provided they can add clinical credibility to the relationship.
Takeaway on channels and partnerships. Build distribution at the point of prescription: pharmacy, telehealth, dietitian networks and subscription delivery aligned to the medication cycle. Partner with retailers on GLP-1 household programmes and category resets, and use online retail to deliver the personalisation and replenishment the segment expects. Measure channel performance by share of GLP-1 household spend, not by store count.
Lesson 5: Volume Is Falling and Value Is Rising, and the Margin Math Has Changed
The food industry's fear about GLP-1 is volume. JPMorgan has estimated that growing use of the medications could remove USD 30 billion to USD 55 billion in annual food and beverage sales by 2030, and Circana projects 2026 food and beverage volume growth of between minus 1 percent and plus 1 percent, with dollar growth of 3 to 5 percent carried by price and mix. But the same data show the counterweight: PwC's United Kingdom survey found that while almost 60 percent of GLP-1 users are buying less food, around 30 percent are trading up, and Boston Consulting Group reports that users are cutting calories but not overall food spend.
For meal replacement, that is a favourable equation. The category sells nutrition per calorie, which is exactly what a consumer with a smaller appetite and a medical reason to eat well will pay more for. The brands moving first are pricing on protein density, completeness and clinical credibility rather than on volume, and are shifting the portfolio toward the formats, ready-to-drink shakes above all, where the premium is easiest to capture.
The capabilities that decide who captures this demand are specific:
Protein-first, nutritionally complete formulations with published evidence.
Phase-specific products for active loss, maintenance and transition off the medication.
Presence at the point of prescription and in GLP-1 household programmes at retail.
Pricing and subscription models built on nutrition per calorie rather than volume.
Claims and labelling that will survive the FDA's "healthy", front-of-package and ultra-processed definitions.
Companies evaluating these competitive dynamics in greater detail can use SRI's Meal Replacement Market analysis to assess product, application, source, channel and regional segments and the positioning of the leading nutrition, consumer goods and direct-selling companies.
Takeaway on pricing and portfolio. Reprice on nutrition density and clinical value, not on volume. Shift mix toward ready-to-drink and complete formats where the premium holds, build subscription economics around the multi-year user, and model the portfolio for a market where units fall and value per unit rises. Protect margin by owning the formulation and the evidence rather than competing on price per shake.
Where the Opportunity Is Concentrating
Value is moving toward protein-dense formats, clinical credibility and the prescription channel.
By product, ready-to-drink shakes are the largest segment and the one best suited to the medicated consumer's need for convenience and completeness, with powders serving the fitness and value buyer and bars and ready meals growing as snack and meal substitutes.
By application, weight management and medical and clinical nutrition are converging into a single GLP-1-driven segment, while sports and fitness nutrition remains the protein-led core and convenience nutrition broadens the base.
By source, plant-based formulations are the fastest growing, dairy remains the quality benchmark for protein, and blended formulations are emerging as the practical compromise on cost, texture and nutrition.
By channel, supermarkets and hypermarkets lead on volume, online retail is gaining on subscription and personalisation, and pharmacies and prescription-adjacent channels are the fastest-growing routes to the medicated consumer.
By geography, North America is the largest market and the epicentre of GLP-1 adoption, Asia Pacific is the fastest growing on urbanisation and rising incomes, and Europe is where regulatory definitions of healthy and ultra-processed food are most advanced.
At the Horizon: What to Watch Over the Next Three Years
The ultra-processed definition. Once the United States finalises a federal definition, the meal replacement category will be sorted into products that qualify as nutrition and products that are classed as ultra-processed. Formulation decisions made now will determine which side of that line a brand lands on.
Generic and oral GLP-1s. As patents expire in some markets and oral formulations expand access, the medicated consumer base will widen beyond the affluent early adopters, and the price point of the companion nutrition will have to follow.
Retailer category resets. Watch which grocers formally reorganise around GLP-1 households, and which brands win the space they create. The first reset cycle will set shelf positions for years.
"The next phase of competition in meal replacement will not be won by the brand with the best-tasting shake. It will be won by the one a prescriber is willing to recommend."
The Strategic Revenue Opportunity
For nutrition and consumer goods companies, the task is to move the portfolio toward protein-dense, clinically credible formats and to reach the consumer at the point of prescription. For ingredient suppliers, the priority is to solve plant protein quality and texture at mass-market cost. For retailers, the opportunity is to own the GLP-1 household with assortment, advice and loyalty. For investors, the signal is evidence and channel: the brands with clinical substantiation and prescription-adjacent distribution are the ones that will hold margin as the category crowds and regulation tightens.
Market intelligence turns these questions into decisions. Segment-level sizing shows where spend is concentrating, competitive benchmarking shows where legacy diet brands are exposed and where clinical nutrition players are strong, and regional analysis shows which markets will reach mass GLP-1 adoption first. This is the path from market signals to strategic insight to revenue impact.
Takeaway on revenue. Treat meal replacement as four revenue pools with different buyers and sales cycles: GLP-1 companion nutrition sold at the point of prescription, protein-led fitness formats, convenience nutrition for the mass market, and clinical products for medically supervised use. Each needs its own evidence base, channel and price architecture. Enter where the consumer is medicated, the purchase repeats for years, and the prescriber can be made an ally.
The Next Leg: Preparing for the Journey Ahead
The defining shift in meal replacement is that the consumer's appetite is now set by a drug, and the category's job has changed from substituting a meal to making every calorie count. That changes the buyer, the product, the channel and the pace. The companies moving first are not the ones with the longest heritage in dieting; they are the ones who have accepted that the customer is a patient and have rebuilt the business around clinical credibility.
The next three years will decide which brands, retailers and ingredient suppliers own the medicated consumer for the following decade. Decision-makers should rebuild the category thesis around GLP-1 households, reformulate to a protein-first specification, treat regulation as a design constraint, build distribution at the point of prescription, and reprice on nutrition density rather than volume. Companies evaluating growth opportunities in this market can use Strategic Revenue Insights' Meal Replacement Market report to assess market size, competitive dynamics, regional opportunities and strategic growth priorities.
Related analysis: Precision Fermentation: How Animal-Free Proteins Are Building a USD 26.1 Billion Market; Mycoprotein: How Fungi Protein Is Scaling Toward a USD 1.19 Billion Market; Artisan Bakery: How Premium Bread Learned to Scale Without Losing Its Craft.
Frequently Asked Questions
How big is the meal replacement market?
Strategic Revenue Insights estimates the global meal replacement market at USD 17.50 billion in 2025, rising to USD 34.10 billion by 2035 at a 6.9 percent compound annual growth rate.
How are GLP-1 drugs affecting meal replacement?
One in five American households now includes a user of a GLP-1 weight-loss medication. Those households buy less food and more protein, which pushes meal replacement toward protein-dense, clinically credible nutrition for medicated consumers.
Which meal replacement products and channels lead?
Ready-to-drink shakes are the largest product segment and plant-based formulations the fastest growing. Supermarkets and hypermarkets are the largest channel while online retail gains share. North America is the largest region and Asia Pacific the fastest growing.
What are the main challenges for meal replacement brands?
Price competition, labelling and health-claim regulation, supply chain pressure and shifting dietary preferences are the main restraints identified in SRI's research.
About the authors: This article was prepared by the Strategic Revenue Insights research team, which combines market intelligence, competitive analysis and strategic advisory for growth-stage, mid-market and enterprise organisations across the food and beverage sector. Sector analyst: Sandeepa Kulkarni, Research Analyst. Our market estimates combine primary research (interviews, surveys and expert panels) with secondary data (industry reports, databases and public disclosures); read more about how Strategic Revenue Insights works. To discuss this market with our analysts, contact our team.
Comments